NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
123 hedge funds and large institutions have $607M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 50 increasing their positions, 28 reducing their positions, and 15 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 28
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
8% more funds holding
Funds holding: 114 → 123 (+9)
1.85% less ownership
Funds ownership: 61.57% → 59.72% (-1.9%)
17% less capital invested
Capital invested by funds: $733M → $607M (-$126M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Column Group
San Francisco,
California
|
+$26.2M |
| 2 |
BlackRock
New York
|
+$14.3M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$11M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCP
Rho Capital Partners
New York
|
-$57.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26.2M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$14.6M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$5.37M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$4.66M |
NGM Hedge Fund Activity: Q2 2022 in Review
123 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2022, worth a combined $607M — down 17% from $733M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new NGM positions and 15 closed out — a net gain of 11 holders — while 50 added to existing stakes and 28 trimmed.
The largest buyer was Column Group, adding an estimated $26.2M. The largest seller was Rho Capital Partners, exiting entirely with an estimated $57.4M sold.
- 123 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2022, up from 114 in Q1 2022.
- Funds reported $607M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2022, down 17% quarter-over-quarter.
- 26 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2022 and 15 closed out, a net change of +11 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q2 2022 was Column Group, an estimated $26.2M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2022 was Rho Capital Partners, an estimated $57.4M sold.
Based on aggregated 13F filings for Q2 2022.